UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: ai

The challenges facing the pathology department

It was a pleasure to welcome key opinion leaders to a discussion on accelerating the impact of AI through 100% digitization of the pathology workflow. Chaired by Peter Hamilton, Head of Research at Philips Digital & Computational Pathology, barriers to adoption, what drives the need and how do we reap the benefits were all on the agenda.

If you weren’t able to make the panel discussion, this six-part blog series will uncover what was discussed. Alternatively, you can watch the recording here.

Read More

Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines

Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.

Read More

Integrating AI and HCI for drug discovery

Bringing new therapeutics to patients is easier said than done due to the enormous intrinsic complexity behind being efficacious and safe.

Read More

Cutting through the hype: Brandon Allgood talks AI and machine learning

When we last spoke, Brandon Allgood told us about The Future of AI. This week, we caught up with Brandon and spoke about drug discovery and machine learning algorithms.

Read More

Analytics and Big Data in Pharma

Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.

Read More

The Future of AI: A Q&A with Brandon Allgood

Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.

Here, Brandon talks about what he thinks the future holds for AI and machine learning:

Read More

The Optimization of Digital Pathology Technology: An Open Letter from Yukako Yagi

Dear Colleagues,

As the field of digital pathology continues to evolve, we are discovering new and exciting ways to use and apply the technology. Digital Pathology is entering a new era, revealing an unprecedented breadth and depth of information for cancer research and diagnosis. Whole slide imaging (WSI) will take an important role in the development of future technologies, imaging modalities and systems, and impact clinical workflows, yielding a comprehensive multi-dimensional analysis that would otherwise be impossible!

Read More

New Digital Pathology Strategies & Re-Imagined Diagnostic Services in the UK

An evaluation of the UK’s pathology capacity by Cancer Research UK (CRUK) has identified that over the next 5-10 years “there is likely to be a severe crisis.” The report highlights a 4.5% year-on-year increase in the number and complexity of histopathology requests since 2007/08; the majority of which are for the investigation of cancer.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive